Selective GlyT1 Inhibitors: Discovery of [4-(3-Fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a Promising Novel Medicine To Treat Schizophrenia
Journal of Medicinal Chemistry2010Vol. 53(12), pp. 4603–4614
Citations Over TimeTop 10% of 2010 papers
Emmanuel Pinard, Alexander Alanine, Daniela Alberati, Markus Bender, Edilio Borroni, Patrick Bourdeaux, Virginie Brom, Serge Burner, Holger Fischer, Dominik Hainzl, Remy Halm, Nicole Hauser, Synèse Jolidon, Judith A. Lengyel, Hans-Peter Marty, Thierry Meyer, Jean‐Luc Moreau, Roland Mory, Robert Narquizian, Mathias Nettekoven, Roger D. Norcross, Bernd Puellmann, Philipp Schmid, Sébastien Schmitt, Henri Stalder, Roger Wermuth, Joseph G. Wettstein, Daniel Zimmerli
Abstract
The GlyT1 transporter has emerged as a key novel target for the treatment of schizophrenia. Herein, we report on the optimization of the 2-alkoxy-5-methylsulfonebenzoylpiperazine class of GlyT1 inhibitors to improve hERG channel selectivity and brain penetration. This effort culminated in the discovery of compound 10a (RG1678), the first potent and selective GlyT1 inhibitor to have a beneficial effect in schizophrenic patients in a phase II clinical trial.
Related Papers
- → Association of the hERG mutation with long-QT syndrome type 2, syncope and epilepsy(2016)19 cited
- → Time is a critical factor in evaluating indirect hERG inhibition by Oligonucleotide Therapeutics(2022)
- → Robust Deep Learning Architecture for hERG-related Cardiotoxicity Prediction on Small-Scale Dataset(2022)
- → ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВ(2024)